Alcon Ag · SIX:ALC
Alcon — American Academy of Ophthalmology (AAO) Annual Meeting 2008 Investor Meeting
33 slides from Alcon's conference presentation, Nov 10, 2008
Slide 1: Slides used during the Alcon, Inc. AAO Presentation
Exhibit 99.1 Alcon, Inc. Slides used during the Alcon, Inc. AAO Presentation November 7, 2008
Slide 2: Safe Harbor Statement
Safe Harbor Statement Thls presentation, made on November 7, 2008, Includes forward-looking Statements based on current expectations and Alcon does not undertake ihe obligation fo update the forward-looking information or statements. These expectations could differ materially from actual resutts and
Slide 3: Topic Speaker
Topic Speaker Opening Remarks Cary Rayment Product Growth Drivers Kevin Buehler Question & Answer Session Cary Rayment Rick Croarkin Kevin Buehler Sabri Markabi, PhD siamese Alcon
Slide 4: Long Term Favorable Business Model
Long Term Favorable Business Model a Diversified business model with multiple sources for growth ~ Global reach and leadership unmatched a Solid long term fundamentals underlie our markets and our business = New products in pipeline at all stages of development = Long history of solid execution and
Slide 5: Alcon in the Current Market Environment
Alcon in the Current Market Environment = Clear appreciation for current economic environment and potential impact on markets and our business a Expect to deliver lower end of long term organic growth range in 2009 - Economic impacts and TobraDex® = Facing currency headwind of 5-6% in 2009 (at curre
Slide 6: Research and Development Projects
Research and Development Projects Glaucoma = AZARGA® anew glaucoma combination ex-US {Approval Pending) = Travatan® Z clinical differentiation (Phase IY} = Anccortave Acetate fer Glaucoma studies and represents a shift in patient compliance {Phase Il} Retina = RTKi compound for wet AMD [Phase Il} =
Slide 7: Product Growth Drivers
Product Growth Drivers Advanced Technology JOLs New Equipment Platforms New Glaucoma Formulations sium Alcon
Slide 8: Product Growth Drivers
Product Growth Drivers Advanced Technology IOLs New Equipment Platforms New Glaucoma Formulations sium Alcon
Slide 9: Alcon Remains the #1 Choice in PC-IOLs
Alcon Remains the #1 Choice in PC-IOLs PC-IOL Usage Share as a % of Surgeons 4@ 2007 3Q 2068 mAeSTORG AcSTORG Aap heic BReSTOR® ReSTOR@ Aspheric mReZoom* 5 rote . oe Crystulens’ et HD* “Trademarks are property of their respective owners. Sere a Werte Ke isan Alcon
Slide 10: AcrySof ReSTOR +3.0 Key Benefits
AcrySof® ReSTOR® +3.0 Key Benefits ( AcrySof* ReSTOR* +3.0 - Received CE mark in Q3 2007 * Announced ex-U,S, launch at ESCRS in September * Filed PMA with FDA in Q2 2008, expecting response by early 2009 Aspheric acrylic design based on highly biocompatible AcrySof® Materials Maintains all visual pe
Slide 11: Visual Acuity Comparison of the ReSTOR Lenses
Visual Acuity Comparison of the ReSTOR® Lenses Improved Vision at All Distances ReSTOR® Aspheric ReSTOR® Aspheric +3.0 +4.0 20/20 or Better 31.2% 8.4% 20/25 or Better 61.8% 21.4% 20/32 or Better 86.2% 49.6% 20/40 or Better 94.9% 71.8% Worse than 20/40 5.1% 28.2% Notes Comparicon of AorySotl™ RoSTOR®
Slide 12: Mean Visual Disturbances
Mean Visual Disturbances ReSTOR® Aspheric +40 ReSTOR® Aspneric +30 *Tradomarks aro property of thoir rocpoctive owner Images provided by Jim Schwiegoring at tho Univorcity of Arizona
Slide 13: AcrySof Toric Distinguishing Characteristics
AcrySof® Toric Distinguishing Characteristics Member of the proven AcrySof® platform AcrySof® Toric Diopter extensions are in development
Slide 14: Near Full Penetration of AcrySof Toric
Near Full Penetration of AcrySof® Toric Penetration Rate Among U.S. Unit Market Share for Toric Implanting Surgeons Toric Lenses as of Q2 2008 AcrySof® Toric 97% % of Surgeons \ Staar Toric aor 2Q07 Wor 4Q07 1008 2QoR ICE Ts AerySof” Torie vource: Ws ZY interna Aicon uate Source: Market Scope G2 200
Slide 15: AcrySof Phakic Lens Effects on Visual Acuity
AcrySof® Phakic Lens Effects on Visual Acuity Change in Best Spectacle Corrected Visual Acuity from Pre-Operation Over 50% of patients achieved one line or more 50% 5 increase over pre-op at both 1 and 3 years 43% wo. | 1 Year 3 Years 39% aah 3% 30% 20% 4 Uh 14% 10% - 5% 5% 0% 0% o% 1% 1% 1% | o% —_
Slide 16: AcrySof Phakic: Effects on Endothelial Cells
AcrySof® Phakic: Effects on Endothelial Cells Mean Chronic Loss in Central ECD Minimal effect on Chronic Endothelial Cell Density (ECD) with year 1 and 2 show gains in ECD Bs j os | i Gbsecen tl ” 0 OS 4 15 a r r r r 1 15 2 25 3 Postoperative Visit (years) Data shown is mean chance with upper 90% co
Slide 17: Alcon at the AAO: IOLs
Alcon at the AAO: IOLs = SOE: Astigmatism Correction with Alcon Toric IOLs - erp 1145, 2:00-3:30 p.m., Geurgia World Congress Center, Level 1, Hall B- =» Common Pitfalls of Presbyopia-Correcting |OLs: How to Predict and Prevent Failure - Sunday, 11/9, 3:15-5:30 p.m., Georgia World Congress Center, R
Slide 18: Product Growth Drivers
Product Growth Drivers Advanced Technology |JOLs New Equipment Platforms New Glaucoma Formulations sium Alcon
Slide 19: LAUREATE World Phaco System
LAUREATE™ World Phaco System LAUREATE™ Target Strategy = Entry to mid-level phace system i » Significant potantial in emerging markets = Enables an entry point to the Alcon portfolio of products for lower tier surgeons LAUREATE™ Features = Traditional ultrasqund technology without OZil® torsional ha
Slide 20: Vitreoretinal Equipment Share Development
Vitreoretinal Equipment Share Development U.S. ACCURUS® Installed Base Share Growth 80 B4% 30 5 ¢ lila dial da dil Historical estimation based on trends, y internal Aleon Curvaye, 4909 ~2000 THY sium Alcon
Slide 21: CONSTELLATION Improvements over ACCURUS
CONSTELLATION® Improvements over ACCURUS* PRe@UM ANCE = VEC Injectonfextrusion Pneumatic Sciccorc/Forceps Fluidics = Vac Control 6SOmm iq = Flow Contret an se Aitnmated FiAX a
Slide 22: ULTRAVIT Vitrectomy Probe Features
ULTRAVIT® Vitrectomy Probe Features a High Speed Vitrectomy Probe - 5000 CPM and variable duty cycle control (standard 2500 CPM) - Allows for more physician control and enables work closer to the retina
Slide 23: Alcon at the AAO: Surgical Equipment
Alcon at the AAO: Surgical Equipment a CONSTELLATION® Vision System Clinical Experiences Panel Discussion - Sunday, 11/9, 9:45 a.m., Georgia World Congress Center, Alcon Booth #1300 =» CONSTELLATION® Vision System: Challenging Cases Panel Discussion - Sunday, 1149, 1:30 p.m., Georgia World Congress
Slide 24: Product Growth Drivers
Product Growth Drivers Advanced Technology IOLs New Equipment Platforms New Glaucoma Formulations sium Alcon
Slide 25: Growing the TRAVATAN Family
Growing the TRAVATAN® Family U.S. Rx Share of TRAVATAN Z* as a Alcon Global Prostaglandin Market Share Percentage of the Total TRAVATAN® Franchise TRAVATAN® Family has gained 3.8 share points TRAVATAN?® Franchise Is bpelibal rrp 6.3 share following DuoTrav™ and TRAVATAN Z® launches bpelibal rrp sinc
Slide 26: Continued Development of DuoTrav
Continued Development of DuoTrav™ DuoTrav™ Market Share in EV, Australia and Canada 26% 24.2% : alll C206 Q306 Q406 O167 Q207 Q307 Qd07 Q108 Q258 foun M5, siamese Alcon
Slide 27: Azopt Gaining Global Market Share
Azopt® Gaining Global Market Share Global TC velo 60% - —®-Azopt® -#-Trusopt’ §5.8% S8% 4 soy | “85% 14.2 Snare Point Spread 40.8% 45% - 41.7% 40% ' ' ' ' ’ ’ : , QI06 Q406 Qi107 Q207 Qla07 407 gioe gqeos * Trutogt te « regietered trademark of Merck Souroo: IMS
Slide 28: Expanding Glaucoma Product Portfolio
Expanding Glaucoma Product Portfolio AZARGA® Suspension a Brinzolamide 1% / Timolol 0.5% fixed combination = Powerful efficacy, superior comfort = European marketing application filed in 4Q 2007 — Positive opinion received
Slide 29: Favorable Patient Response
Favorable Patient Response Ocular Comfort Patient Preference 60% GOSsoPT* 40% - 20% % WSith nc Ocular Discomfart 0% 3 Fy AZARGA® AZARGA cosopi" Suspension Sus pension * COGOPT is a reqisterad trademark of Marck ‘Ver AO Fears 8 rma hh +l a A cir-eres comet sheyert ic care Miser TK Marstr as Mt eee AO
Slide 30: Gaining Market Share in Pharmaceuticals
Gaining Market Share in Pharmaceuticals RX Growth fe za Septembe a 2008 Brand Market Market TRAVATAN® Family 16.3% 8.3% m - 44% Azopi® 7.7% 6.1% 5.1% Vigamox®” 20.6% 7.7% -0.7% TobraDex®” 6.8% 7.4% 0.8% NEVANAC® : 3.4% 11.5% Patanol® + Pataday™ 2.3% -3.1% CIPRQDEX” 7 Cipra HC 4.3% * Moxifinxarin, th
Slide 31: Alcon at the AAO: Glaucoma
Alcon at the AAO: Glaucoma a Optimizing Patient Care: Managing Glaucoma and Ocular Surface Disease: A Care-Based Interactive Discussion (an Ophthalmology Times Educational Symposium) - Sunday, 11/9, Marriott Marquis * 6:00-6:30 a.m. Registration * 6:30-8:00 a.m. Symposium a A Study of Anecortave Ace
Slide 32: Alcon Investor Meeting at AAO
Alcon Investor Meeting at AAO November 7, 2008
Slide 33: AcrySof Phakic Lens Attributes
AcrySof® Phakic Lens Attributes Unique design and biocompatible material Low haptic force and vault dynamic response Small incision delivery with minimal endothelial cell loss Effective visual correction supported by clinical results Refractive power range of -6.0 to -16.5 Potential expansion to tor
Alcon — American Academy of Ophthalmology (AAO) Annual Meeting 2008 Investor Meeting on 6ix